Yesterday, spots of pink could be spotted on the streets of San Francisco, and it wasn’t a coincidence. Members of the ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specialises in the treatment of rare gastrointestinal cancer GIST. GSK said in a statement that it had agreed ...

Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.

On Monday, GSK plc (GSK) stock saw a decline, ending the day at $32.7 which represents a decrease of $-0.39 or -1.18% from the prior close of $33.09. The stock opened at $32.74 and touched a low of ...

GSK PLC GSK shares shed 2.82% to £12.94 Tuesday, on what proved to be an all-around rough trading session for the stock ...

J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...

Shares of GSK PLC GSK slipped 1.37% to £13.31 Monday, on what proved to be an all-around rough trading session for the stock ...